| Year |
Citation |
Score |
| 2024 |
Maddirala AR, Tamadonfar K, Pinkner JS, Sanick D, Hultgren SJ, Janetka JW. Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections. Journal of Medicinal Chemistry. PMID 38308631 DOI: 10.1021/acs.jmedchem.3c02128 |
0.312 |
|
| 2024 |
Jones VT, Graves-Deal R, Cao Z, Bogatcheva G, Ramirez MA, Harmych SJ, Higginbotham JN, Sharma V, Damalanka VC, Wahoski CC, Joshi N, Irudayam MJ, Roland JT, Ayers GD, Liu Q, ... ... Janetka JW, et al. Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer. Cellular and Molecular Life Sciences : Cmls. 81: 28. PMID 38212428 DOI: 10.1007/s00018-023-05071-5 |
0.776 |
|
| 2023 |
Mekapogu AR, Xu Z, Pothula S, Perera C, Pang T, Hosen SMZ, Damalanka V, Janetka J, Goldstein D, Pirola R, Wilson J, Apte M. HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis. Cancer Letters. 568: 216286. PMID 37354984 DOI: 10.1016/j.canlet.2023.216286 |
0.774 |
|
| 2021 |
Damalanka VC, Voss JJLP, Mahoney MW, Primeau T, Li S, Klampfer L, Janetka JW. Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression. Journal of Medicinal Chemistry. 64: 18158-18174. PMID 34902246 DOI: 10.1021/acs.jmedchem.1c01671 |
0.818 |
|
| 2021 |
Mahoney M, Damalanka VC, Tartell MA, Chung DH, Lourenço AL, Pwee D, Mayer Bridwell AE, Hoffmann M, Voss J, Karmakar P, Azouz NP, Klingler AM, Rothlauf PW, Thompson CE, Lee M, ... ... Janetka JW, et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34635581 DOI: 10.1073/pnas.2108728118 |
0.801 |
|
| 2021 |
Mahoney M, Damalanka VC, Tartell MA, Chung DH, Lourenco AL, Pwee D, Mayer Bridwell AE, Hoffmann M, Voss J, Karmakar P, Azouz N, Klingler AM, Rothlauf PW, Thompson CE, Lee M, ... ... Janetka JW, et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Biorxiv : the Preprint Server For Biology. PMID 34131661 DOI: 10.1101/2021.05.06.442935 |
0.803 |
|
| 2021 |
Tyagi R, Bulman CA, Cho-Ngwa F, Fischer C, Marcellino C, Arkin MR, McKerrow JH, McNamara CW, Mahoney M, Tricoche N, Jawahar S, Janetka JW, Lustigman S, Sakanari J, Mitreva M. An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease. Pathogens (Basel, Switzerland). 10. PMID 33466870 DOI: 10.3390/pathogens10010071 |
0.731 |
|
| 2020 |
Damalanka VC, Maddirala AR, Janetka JW. Novel approaches to glycomimetic design: Development of small molecular weight lectin antagonists. Expert Opinion On Drug Discovery. PMID 33337918 DOI: 10.1080/17460441.2021.1857721 |
0.774 |
|
| 2020 |
Janetka JW, Hopper AT, Yang Z, Barks J, Savari Dhason M, Wang Q, Sibley LD. Optimizing pyrazolopyrimidine inhibitors of calcium dependent protein kinase 1 for treatment of acute and chronic toxoplasmosis. Journal of Medicinal Chemistry. PMID 32420739 DOI: 10.1021/Acs.Jmedchem.0C00419 |
0.464 |
|
| 2020 |
Mekapogu A, Xu Z, Pothula S, Perera C, Pang T, Hosen Z, Janetka J, Damalanka V, Mahoney M, Klampfer L, Goldstein D, Pirola R, Wilson J, Apte M. Inhibition of both the ligand and receptor of the hepatocyte growth factor/c-MET pathway, in combination with chemotherapy, retards progression of PanIN lesions in KPC mice Pancreatology. 20: S39-S40. DOI: 10.1016/j.pan.2020.07.049 |
0.697 |
|
| 2019 |
Yang B, Hird AW, Bodnarchuk MS, Zheng X, Dakin L, Su Q, Daly K, Godin R, Hattersley MM, Brassil P, Redmond S, John Russell D, Janetka JW. Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254). Bioorganic & Medicinal Chemistry. 115227. PMID 31862310 DOI: 10.1016/J.Bmc.2019.115227 |
0.437 |
|
| 2019 |
Damalanka VC, Wildman SA, Janetka JW. Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin. Medchemcomm. 10: 1646-1655. PMID 31803403 DOI: 10.1039/C9Md00234K |
0.826 |
|
| 2019 |
Tyagi R, Elfawal MA, Wildman SA, Helander J, Bulman CA, Sakanari J, Rosa BA, Brindley PJ, Janetka JW, Aroian RV, Mitreva M. Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics. Scientific Reports. 9: 9085. PMID 31235822 DOI: 10.1038/S41598-019-45548-7 |
0.819 |
|
| 2019 |
Damalanka VC, Janetka JW. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2. Future Medicinal Chemistry. PMID 30945556 DOI: 10.4155/Fmc-2018-0446 |
0.786 |
|
| 2018 |
Damalanka VC, Han Z, Karmakar P, O'Donoghue AJ, La Greca F, Kim T, Pant S, Helander J, Klefström J, Craik CS, Janetka JW. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology. Journal of Medicinal Chemistry. PMID 30571119 DOI: 10.1021/Acs.Jmedchem.8B01536 |
0.785 |
|
| 2018 |
Maddirala A, Klein RD, Pinkner J, Kalas V, Hultgren SJ, Janetka JW. Biphenyl Gal and GalNAc FmlH Lectin Antagonists of Uropathogenic E. coli (UPEC): Optimization through iterative rational drug design. Journal of Medicinal Chemistry. PMID 30540910 DOI: 10.1021/Acs.Jmedchem.8B01561 |
0.795 |
|
| 2018 |
Tyagi R, Maddirala AR, Elfawal M, Fischer C, Bulman C, Rosa BA, Gao X, Chugani R, Zhou M, Helander J, Brindley P, Tseng CC, Greig IR, Sakanari J, Wildman SA, ... ... Janetka JW, et al. Small molecule inhibitors of metabolic enzymes repurposed as a new class of anthelmintics. Acs Infectious Diseases. PMID 29718656 DOI: 10.1021/Acsinfecdis.8B00090 |
0.744 |
|
| 2018 |
Kalas V, Hibbing ME, Maddirala AR, Chugani R, Pinkner JS, Mydock-McGrane LK, Conover MS, Janetka JW, Hultgren SJ. Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection. Proceedings of the National Academy of Sciences of the United States of America. PMID 29507247 DOI: 10.1073/Pnas.1720140115 |
0.767 |
|
| 2018 |
Yang B, Vasbinder M, Hird AW, Su Q, Wang H, Yu Y, Toader D, Lyne PD, Read JA, Breed J, Ioannidis S, Deng C, Grondine M, DeGrace N, Whitston D, ... ... Janetka JW, et al. Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors. Journal of Medicinal Chemistry. PMID 29301085 DOI: 10.1021/Acs.Jmedchem.7B01490 |
0.463 |
|
| 2017 |
Owusu BY, Thomas S, Venukadasula P, Han Z, Janetka JW, Galemmo RA, Klampfer L. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget. 8: 63014-63025. PMID 28968967 DOI: 10.18632/Oncotarget.18260 |
0.801 |
|
| 2017 |
Rutaganira FU, Barks J, Dhason MS, Wang Q, Lopez MS, Long S, Radke JB, Jones NG, Maddirala AR, Janetka JW, El Bakkouri M, Hui R, Shokat KM, Sibley LD. Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii. Journal of Medicinal Chemistry. PMID 28933846 DOI: 10.1021/Acs.Jmedchem.7B01192 |
0.826 |
|
| 2017 |
Owusu BY, Thomas S, Venukadasula P, Han Z, Janetka JW, Galemmo RA, Klampfer L. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget. PMID 28624806 DOI: 10.18632/oncotarget.18260 |
0.791 |
|
| 2017 |
Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, Dodson KW, Pinkner JS, Fremont DH, Janetka JW, Remaut H, Gordon JI, Hultgren SJ. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature. PMID 28614296 DOI: 10.1038/Nature22972 |
0.336 |
|
| 2017 |
Mydock-McGrane LK, Hannan TJ, Janetka JW. Rational Design Strategies for FimH Antagonists: New Drugs on the Horizon for Urinary Tract Infection and Crohn's Disease. Expert Opinion On Drug Discovery. PMID 28506090 DOI: 10.1080/17460441.2017.1331216 |
0.381 |
|
| 2017 |
Owusu BY, Galemmo R, Janetka J, Klampfer L. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment Cancers. 9: 35. PMID 28420162 DOI: 10.3390/Cancers9040035 |
0.409 |
|
| 2017 |
Kalas V, Pinkner JS, Hannan TJ, Hibbing ME, Dodson KW, Holehouse AS, Zhang H, Tolia NH, Gross ML, Pappu RV, Janetka J, Hultgren SJ. Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. Science Advances. 3: e1601944. PMID 28246638 DOI: 10.1126/Sciadv.1601944 |
0.305 |
|
| 2016 |
Mydock-McGrane L, Cusumano Z, Han Z, Binkley J, Kostakioti M, Hannan T, Pinkner JS, Klein RD, Kalas V, Crowley J, Rath NP, Hultgren SJ, Janetka JW. Anti-virulence C-mannoisdes as antibiotic-sparing, oral therapeutics for urinary tract infections. Journal of Medicinal Chemistry. PMID 27689912 DOI: 10.1021/Acs.Jmedchem.6B00948 |
0.773 |
|
| 2016 |
Simpson C, Jones NG, Hull-Ryde EA, Kireev D, Stashko M, Tang K, Janetka J, Wildman SA, Zuercher WJ, Schapira M, Hui R, Janzen W, Sibley LD. Identification of small molecule inhibitors that block the Toxoplasma gondii rhoptry kinase ROP18. Acs Infectious Diseases. 2: 194-206. PMID 27379343 DOI: 10.1021/Acsinfecdis.5B00102 |
0.453 |
|
| 2016 |
Han Z, Harris PK, Karmakar P, Kim T, Owusu BY, Wildman SA, Klampfer L, Janetka JW. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer. Chemmedchem. PMID 26889658 DOI: 10.1002/Cmdc.201500600 |
0.821 |
|
| 2016 |
Wang Q, Heizer E, Rosa BA, Wildman SA, Janetka JW, Mitreva M. Characterization of parasite-specific indels and their proposed relevance for selective anthelminthic drug targeting. Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases. PMID 26829384 DOI: 10.1016/J.Meegid.2016.01.025 |
0.376 |
|
| 2016 |
Jarvis C, Han Z, Kalas V, Klein R, Pinkner JS, Ford B, Binkley J, Cusumano CK, Cusumano Z, Mydock-McGrane L, Hultgren SJ, Janetka JW. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. Chemmedchem. PMID 26812660 DOI: 10.1002/Cmdc.201600006 |
0.805 |
|
| 2016 |
Liu F, Han Z, Karmakar P, Li T, Janetka JW, Lai A. DDIS-10. TARGETING HGF/MET IN GBM BY RESTORING SPINT2 FUNCTION Neuro-Oncology. 18: vi49-vi49. DOI: 10.1093/Neuonc/Now212.201 |
0.758 |
|
| 2016 |
Simpson C, Jones NG, Hull-Ryde EA, Kireev D, Stashko M, Tang K, Janetka JW, Wildman SA, Zuercher WJ, Schapira M, Hui R, Janzen W, Sibley LD. Identification of Small Molecule Inhibitors That Block the Toxoplasma gondii Rhoptry Kinase ROP18 Acs Infectious Diseases. 2: 194-206. DOI: 10.1021/acsinfecdis.5b00102 |
0.345 |
|
| 2016 |
Han Z, Harris PKW, Karmakar P, Kim T, Owusu BY, Wildman SA, Klampfer L, Janetka JW. Back Cover: α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer (ChemMedChem 6/2016) Chemmedchem. 11: 640-640. DOI: 10.1002/Cmdc.201600124 |
0.795 |
|
| 2016 |
Jarvis C, Han Z, Kalas V, Klein R, Pinkner JS, Ford B, Binkley J, Cusumano CK, Cusumano Z, Mydock-McGrane L, Hultgren SJ, Janetka JW. Cover Picture: Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI (ChemMedChem 4/2016) Chemmedchem. 11: 351-351. DOI: 10.1002/Cmdc.201600045 |
0.761 |
|
| 2015 |
Mydock-McGrane LK, Cusumano ZT, Janetka JW. Mannose-Derived FimH Antagonists: A promising anti-virulence therapeutic strategy for Urinary Tract Infections and Crohn's Disease. Expert Opinion On Therapeutic Patents. PMID 26651364 DOI: 10.1517/13543776.2016.1131266 |
0.343 |
|
| 2015 |
Greene SE, Hibbing ME, Janetka J, Chen SL, Hultgren SJ. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli. Mbio. 6. PMID 26126855 DOI: 10.1128/Mbio.00820-15 |
0.339 |
|
| 2015 |
Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets. Bioorganic & Medicinal Chemistry. 23: 2328-43. PMID 25882520 DOI: 10.1016/J.Bmc.2015.03.072 |
0.822 |
|
| 2014 |
Han Z, Harris PK, Jones DE, Chugani R, Kim T, Agarwal M, Shen W, Wildman SA, Janetka JW. Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. Acs Medicinal Chemistry Letters. 5: 1219-24. PMID 25408834 DOI: 10.1021/Ml500254R |
0.801 |
|
| 2014 |
Janetka J, Han Z, Harris P, Wildman S. Abstract 2523: Mechanism-based inhibitors of HGFA, matriptase and hepsin for breast cancer treatment Cancer Research. 74: 2523-2523. DOI: 10.1158/1538-7445.Am2014-2523 |
0.799 |
|
| 2013 |
Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, Hultgren SJ, Schembri MA. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. The Journal of Infectious Diseases. 208: 921-8. PMID 23737602 DOI: 10.1093/Infdis/Jit245 |
0.329 |
|
| 2012 |
Guiton PS, Cusumano CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, Caparon MG, Hultgren SJ. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrobial Agents and Chemotherapy. 56: 4738-45. PMID 22733070 DOI: 10.1128/Aac.00447-12 |
0.752 |
|
| 2012 |
Yang B, Hird AW, Russell DJ, Fauber BP, Dakin LA, Zheng X, Su Q, Godin R, Brassil P, Devereaux E, Janetka JW. Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO Bioorganic and Medicinal Chemistry Letters. 22: 4907-4911. PMID 22704236 DOI: 10.1016/J.Bmcl.2012.04.104 |
0.451 |
|
| 2012 |
Kostakioti M, Hadjifrangiskou M, Cusumano CK, Hannan TJ, Janetka JW, Hultgren SJ. Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection Infection and Immunity. 80: 2826-2834. PMID 22665375 DOI: 10.1128/Iai.00283-12 |
0.336 |
|
| 2012 |
Oza V, Ashwell S, Almeida L, Brassil P, Breed J, Deng C, Gero T, Grondine M, Horn C, Ioannidis S, Liu D, Lyne P, Newcombe N, Pass M, Read J, ... ... Janetka J, et al. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. Journal of Medicinal Chemistry. 55: 5130-42. PMID 22551018 DOI: 10.1021/Jm300025R |
0.406 |
|
| 2012 |
Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, Campbell S, Henderson JP, Hultgren SJ, Janetka JW. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. Journal of Medicinal Chemistry. 55: 3945-59. PMID 22449031 DOI: 10.1021/Jm300165M |
0.78 |
|
| 2011 |
Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, Henderson JP, Janetka JW, Hultgren SJ. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Science Translational Medicine. 3: 109ra115. PMID 22089451 DOI: 10.1126/Scitranslmed.3003021 |
0.771 |
|
| 2011 |
Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics Trends in Molecular Medicine. 17: 88-96. PMID 21087899 DOI: 10.1016/J.Molmed.2010.10.009 |
0.369 |
|
| 2011 |
Janetka JW, Agarwal M, Jones DE. Abstract LB-197: Hepatocyte Growth Factor Activator (HGFA) Inhibitors of c-MET/RON Kinase Signaling Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-197 |
0.673 |
|
| 2010 |
Oza V, Ashwell S, Brassil P, Breed J, Deng C, Ezhuthachan J, Haye H, Horn C, Janetka J, Lyne P, Newcombe N, Otterbien L, Pass M, Read J, Roswell S, et al. Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration. Bioorganic & Medicinal Chemistry Letters. 20: 5133-8. PMID 20673630 DOI: 10.2210/Pdb2X8D/Pdb |
0.403 |
|
| 2010 |
Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, Wildman SA, Hobbs D, Ellenberger T, Cusumano CK, Hultgren SJ, Janetka JW. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. Journal of Medicinal Chemistry. 53: 4779-92. PMID 20507142 DOI: 10.1021/Jm100438S |
0.776 |
|
| 2009 |
Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Markland W, et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. Journal of Medicinal Chemistry. 52: 6362-8. PMID 19827834 DOI: 10.1021/Jm900630Q |
0.467 |
|
| 2009 |
Janetka JW, Ashwell S. Checkpoint kinase inhibitors: A review of the patent literature Expert Opinion On Therapeutic Patents. 19: 165-197. PMID 19441917 DOI: 10.1517/13543770802653622 |
0.364 |
|
| 2008 |
Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Molecular Cancer Therapeutics. 7: 2955-66. PMID 18790776 DOI: 10.1158/1535-7163.Mct-08-0492 |
0.328 |
|
| 2008 |
Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: New selective inhibitors in clinical trials Expert Opinion On Investigational Drugs. 17: 1331-1340. PMID 18694366 DOI: 10.1517/13543784.17.9.1331 |
0.338 |
|
| 2008 |
Janetka JW, Almeida L, Ashwell S, Brassil PJ, Daly K, Deng C, Gero T, Glynn RE, Horn CL, Ioannidis S, Lyne P, Newcombe NJ, Oza VB, Pass M, Springer SK, et al. Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18: 4242-8. PMID 18547806 DOI: 10.1016/J.Bmcl.2008.05.016 |
0.408 |
|
| 2007 |
Aronov AM, Baker C, Bemis GW, Cao J, Chen G, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Martinez-Botella G, Namchuk MN, Straub J, et al. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. Journal of Medicinal Chemistry. 50: 1280-7. PMID 17300186 DOI: 10.1021/Jm061381F |
0.436 |
|
| 2003 |
Kim IJ, Ullrich T, Janetka JW, Furness MS, Jacobson AE, Rothman RB, Dersch CM, Flippen-Anderson JL, George C, Rice KC. Diaryldimethylpiperazine ligands with μ- and δ-opioid receptor affinity: Synthesis of (+)-4-[(αR)-α -(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl] -N-ethyl-N-phenylbenzamide and (-)-4-[(αR)-α -(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl] -N-ethyl-N-phenylbenzamide Bioorganic and Medicinal Chemistry. 11: 4761-4768. PMID 14556791 DOI: 10.1016/S0968-0896(03)00496-6 |
0.436 |
|
| 2003 |
Janetka JW, Furness MS, Zhang X, Coop A, Folk JE, Mattson MV, Jacobson AE, Rice KC. Enantioconvergent synthesis of (-)-(2R,5S)-1-allyl-2,5-dimethylpiperazine, an intermediate to δ-opioid receptor ligands Journal of Organic Chemistry. 68: 3976-3980. PMID 12737580 DOI: 10.1021/Jo0300385 |
0.605 |
|
| 1998 |
Coop A, Janetka JW, Lewis JW, Rice KC. L-Selectride as a general reagent for the O-demethylation and N-decarbomethoxylation of opium alkaloids and derivatives Journal of Organic Chemistry. 63: 4392-4396. DOI: 10.1021/Jo9801972 |
0.583 |
|
| 1998 |
Coop A, Janetka JW, Lewis JW, Rice KC. L-Selectride as a General Reagent for the O-Demethylation and N-Decarbomethoxylation of Opium Alkaloids and Derivatives Journal of Organic Chemistry. 63: 4392-4396. |
0.449 |
|
| 1997 |
Janetka JW, Rich DH. Total synthesis of the cyclic biphenyl ether peptides K-13 and OF494-III via S(N)Ar macrocyclizations of peptidyl ruthenium π-arene complexes Journal of the American Chemical Society. 119: 6488-6495. DOI: 10.1021/Ja970614C |
0.473 |
|
| 1997 |
Janetka JW, Raman P, Satyshur K, Flentke GR, Rich DH. Novel cyclic biphenyl ether peptide β-strand mimetics and HIV-protease inhibitors Journal of the American Chemical Society. 119: 441-442. DOI: 10.1021/Ja963495U |
0.514 |
|
| 1996 |
Janetka JW, Satyshur KA, Rich DH. A cyclic side-chain-linked biphenyl ether tripeptide: H3N(+)-cyclo-[Phe(4-O)Phe-Phe(3-O)]-OMe.Cl-. Acta Crystallographica. Section C, Crystal Structure Communications. 52: 3112-4. PMID 9015901 |
0.4 |
|
| 1996 |
Janetka JW, Satyshur KA, Rich DH. A cyclic side-chain-linked biphenyl ether tripeptide: H3N+-cyclo-[Phe(4-0)-Phe-Phe (3-0)]-OMe.Cl- Acta Crystallographica Section C: Crystal Structure Communications. 52: 3112-3114. |
0.392 |
|
| 1995 |
Janetka JW, Rich DH. Synthesis of peptidyl ruthenium .pi.-arene complexes: application to the synthesis of cyclic biphenyl ether peptides. Journal of the American Chemical Society. 117: 10585-10586. DOI: 10.1021/Ja00147A026 |
0.475 |
|
| 1995 |
Janetka JW, Rich DH. Synthesis of peptidyl ruthenium π-arene complexes: Application to the synthesis of cyclic biphenyl ether peptides Journal of the American Chemical Society. 117: 10585-10586. |
0.404 |
|
| Show low-probability matches. |